The majority of patients had organic dyspepsia (90.57 %) while the commonest finding was gastritis 69 (43.4 %). Poly(vinylalcohol) Gastroesophageal cancers represented (18) 11.32 % of all findings. There was a positive association between age > 50 years with gastroesophageal cancers (7.639) as well as age less then  50 years and functional dyspepsia (2.794); however, all these were not statistically significant ( P  = 0.006 and ( P  = 0.095, respectively). Conclusions  Organic/structural dyspepsia comprises over 90 % of investigated dyspepsia with 11 % comprising cancer among patients seeking endoscopy at the National Referral Hospital of Uganda.Background and study aims  The goal of this study was to assess surgical resection (SR) of early gastric cancer (EGC) fitting Japanese Gastric Cancer Association (JGCA) endoscopic resection (ER) criteria. Patients and methods  We analyzed EGC data from the national Surveillance, Epidemiology, and End Results (SEER) database from 2010 to 2015. Results  A total of 2219 EGC cases were identified (1074 T1a and 1145 T1b). Of them, 409 met absolute criteria, 219 met expanded 1, 529 expanded 2, and 229 expanded 3. 259 lesions were treated endoscopically while 1007 were surgically resected (20.5 % vs 79.5 %, P  = 0.0001). Temporal analysis showed that the frequency of ER steadily increased while SR proportionally decreased during the study period. Cox proportion regression analysis adjusting for confound variables (including age, gender, and race) showed no significant difference in the risk of mortality following either surgery or endoscopy. Conclusions  EGC can be safely treated with ER. However, EGC meeting JGCA ER criteria is largely treated with SR in the United States.Background and study aims  Incidence of Post-ERCP pancreatitis (PEP) ranges from 1 % to 10 % in unselected patients and as high as 25 % to 30 % in high-risk patients. Rectal indomethacin administered before or immediately after an ERCP and prophylactic pancreatic duct stent placement (PPS) are associated with a reduction in the incidence of PEP. We sought to investigate the utilization rate for prophylactic rectal indomethacin and PPS in average and high-risk patients undergoing ERCP between 2014 and 2019. Patients and methods  We performed a retrospective analysis in the IBM Explorys database, a pooled, national de-identified clinical database of over 72 million unique patients from 26 health care networks and 300 hospitals across the United States from 2014 to 2019. Average and high-risk patients undergoing ERCP were identified using Systematized Nomenclature of Medicine Clinical Terms (SNOMED CT) diagnosis codes. PEP was defined by the presence of SNOMED CT diagnosis of acute pancreatitis and an inpatient admission within 5 days of an ERCP procedure. Results  Out of 31,050 adults who had undergone ERCP from 2014 to 2019, only 10,500 individuals (33.8 %) had a PEP prophylaxis. Rectal indomethacin and PPS accounted for 82.4 % and 12.9 % respectively. Individuals with three risk factors had the highest PEP rates followed by individuals with two risk factors. Conclusions  Only one-third of all patients undergoing ERCP received prophylaxis in the form of rectal indothemacin and/or PPS in this large population-based data. Increased implementation of prophylactic use is needed in patients undergoing ERCP as supported by current guidelines.This research portrays the spatial and temporal progression of super-aging in regions throughout South Korea. Using a single-year population projection considering gross domestic migration, this research identifies which regions will shortly become a super-aged society. A cohort-component method with a migrant pool model is applied. The county-level national population registration data (2000-2018) are aggregated into 37 regions for the model run. In 2020, 16 rural regions will become super-aged societies. By 2029, all 37 regions, including the metropolitan areas, will join the group, with Sejong, the administrative capital, being the last to enter. In brief, the rural areas become super-aged earlier than the metropolitan areas, and within a decade, those 65 years old or older will make up the majority of the national population. Among all the metropolitan areas, Busan, the largest harbor city, will be the first to be super-aged in 2023. Sejong will experience the most radical change between 2020 and 2050. The research outcomes demonstrate that demographic changes in the rural and metropolitan areas are different; hence, the recent population policies, such as promoting fertility, may not work in the rural areas as they have already lost their population momentum due to the extreme and ongoing urbanization throughout the nation. The unstoppable aging will pose adverse effects on future citizens (who are mostly senior) both financially and medically. An increase in health care expenditure and a nationwide blood shortage for transfusion are anticipated, for example. Cervical cancers present major threats to women's health in China. Eliminating cervical cancer in China is a huge challenge, with application of the HPV vaccine, which is an important part. There are currently four HPV vaccines available in China bv-HPV (Wantai, China), bv-HPV, qv-HPV (GSK, UK), and 9v-HPV (MSD, USA). To observe the immunogenicity, efficacy, and safety of these four vaccines in China, we formed the "Chinese Expert Consensus on the Clinical Application of HPV Vaccine." At 7months after vaccination, all vaccinated subjects had the same immunogenic response to either HPV16 or HPV18, ranging from 96 to 100%, and antibody production in girls aged 9-14years was 2-3 times higher than that in adult women. Efficacy of the four vaccines against CIN2 + ranged from 87.3%  to 100%, with prevention of HPV-associated infection reaching 96% ~ 97% at 12months. Clinical trials showed bv-HPV and qv-HPV vaccine were also safe in women aged 18-45years. Clinical trials of the 9v-HPV vaccine are underway. HPV vaccination is currently voluntary and self-paid in China. The "Chinese Expert Consensus on the Clinical Application of HPV Vaccine" will work to promote the application of HPV vaccine in China. In clinical studies, the available HPV vaccines showed excellent efficacy, safety, and immunogenicity in Chinese women. We will continue strengthening screening and encouraging HPV vaccination.In clinical studies, the available HPV vaccines showed excellent efficacy, safety, and immunogenicity in Chinese women. We will continue strengthening screening and encouraging HPV vaccination.